Price movement over the last 24 hours
Alcon AG vs Victoria's Secret & Co — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Victoria's Secret & Co trades at $76.06 (market cap $6.22B). The key difference: Alcon AG is far larger — about 5.3× Victoria's Secret & Co's market cap, and Alcon AG pays a 0.54% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| ALC | VSXY | |
|---|---|---|
Market Cap | $32.69B | $6.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $88.50 |
52-Week Low | $62.02 | $17.70 |
Enterprise Value | $36.28B | $8.86B |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Victoria's Secret (VSXY) trades at $78.25, up 2.01% with strong momentum as the stock benefits from international expansion and improved fundamentals. The company has beaten earnings expectations for three consecutive quarters, with Q1 2026 EPS of $0.60 surpassing the $0.32 estimate. Technical indicators show a neutral overall signal while the stock trades near pivot point resistance at $78. Analyst consensus remains bullish with a $88.56 price target representing 13% upside potential.
The outlook appears positive with international sales growing 44.9% in Q1 2026 and margin recovery underway, though risks include competitive pressures and execution challenges in global expansion. With improving cash flow projections and shareholder support for management's strategy, VSXY offers growth potential but requires monitoring of consumer spending trends and inventory management.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →